SCHEMBL3483852

SCHEMBL3483852

O=C1C(=Cc2ccccc2)S(=O)(=O)c2ccccc21

nearest known ligand 0.77

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.77
ESR2 Q92731 1/20 0.77
ALPI P09923 5/20 0.55
ALPL P05186 4/20 0.55
GPR3 P46089 1/20 0.47
CHEK1 O14757 1/20 0.44
MIF P14174 2/20 0.43
MAOA P21397 2/20 0.42
HPGD P15428 2/20 0.41
MAOB P27338 1/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
STK17B O94768 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15695018 1.00 ESR1 (0.77) ESR1ESR2ALPIALPLGPR3
SCHEMBL12081669 0.86 ESR1 (0.68) ESR1ESR2ALPIALPLGPR3
SCHEMBL15592583 0.78 ESR1 (0.57) ESR1ESR2ALPIALPLGPR3
SCHEMBL4567100 0.77 ESR1 (0.64) ESR1ESR2ALPIALPLGPR3
SCHEMBL13940432 0.77 ESR1 (0.64) ESR1ESR2ALPIALPLGPR3
SCHEMBL11948726 0.76 ESR1 (0.57) ESR1ESR2ALPIALPLMAOA
SCHEMBL16024634 0.76 ESR1 (0.55) ESR1ESR2GPR3MIFMAOB
SCHEMBL12901143 0.75 ESR1 (0.50) ESR1ESR2ALPIALPLGPR3
SCHEMBL31472931 0.74 GPR3 (0.75) ESR1ESR2GPR3CHEK1MAOA
SCHEMBL29368441 0.74 GPR3 (0.75) ESR1ESR2GPR3CHEK1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2601943-B1 Anti-cancer composition containing chalcone compounds SEOUL NAT UNIV IND FOUNDATION (KR) 2015-07-22 EP claimed
US-20130178533-A1 COMPOSITION FOR DIAGNOSING, TREATING, AND PREVENTING LIVER DISEASE SNU R&DB FOUNDATION (KR) 2013-07-11 US claimed
EP-2601943-A1 Anti-cancer composition containing chalcone compounds Seoul National University Industry Foundation (KR) 2013-06-12 EP claimed
US-20100068730-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) 2010-03-18 US claimed
US-9057725-B2 Composition for diagnosing, treating, and preventing liver disease SNU R&DB FOUNDATION (KR) 2015-06-16 US disclosed
US-20130178533-A1 COMPOSITION FOR DIAGNOSING, TREATING, AND PREVENTING LIVER DISEASE SNU R&DB FOUNDATION (KR) 2013-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068730-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS TM9SF4, TM9SF2, TM9SF3 ESR1 330/4885ESR2 1532/4885ALPI 4026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.